| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
100 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
111 |
| Net Income (TTM) (Millions $) |
-232 |
| Cash Flow (TTM) (Millions $) |
83 |
| Capital Exp. (TTM) (Millions $) |
2 |
Business Description
InterMune Inc. was a biotechnology company founded in 1998 and based in California, United States. The company focused on researching, developing, and commercializing therapies for the treatment of serious respiratory and orphan fibrotic diseases.
One of the key products developed by Intermune was Esbriet (pirfenidone), which was approved for the treatment of idiopathic pulmonary fibrosis (IPF) in several countries. IPF is a chronic and progressive lung disease that causes scarring of the lung tissue, leading to difficulty in breathing and reducing lung function. Esbriet helps to slow down the progression of IPF and improve lung function.
InterMune also conducted research into other potential therapies for diseases with high unmet medical needs, such as hepatitis C and nonalcoholic steatohepatitis (NASH). The company aimed to develop innovative treatments to address significant gaps in the current treatment options available for these diseases.
In 2014, Roche Holdings AG acquired Intermune Inc. for approximately $8.3 billion, gaining access to the company's portfolio of respiratory disease treatments. Following the acquisition, Intermune became a wholly-owned subsidiary of Roche and continued to operate under the Roche umbrella.
However, as of my last update in 2021, Intermune Inc. is no longer an independent company and its operations have been integrated into Roche's broader biopharmaceutical operations.
|
%